These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26683526)

  • 1. Treating to target in major depressive disorder: response to remission to functional recovery.
    McIntyre RS; Lee Y; Mansur RB
    CNS Spectr; 2015 Dec; 20 Suppl 1():20-30; quiz 31. PubMed ID: 26683526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.
    McIntyre RS; Xiao HX; Syeda K; Vinberg M; Carvalho AF; Mansur RB; Maruschak N; Cha DS
    CNS Drugs; 2015 Jul; 29(7):577-89. PubMed ID: 26290264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognition in major depressive disorder: a 'Systemically Important Functional Index' (SIFI).
    McIntyre RS; Lee Y
    Curr Opin Psychiatry; 2016 Jan; 29(1):48-55. PubMed ID: 26575300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New standard of depression treatment: remission and full recovery.
    Bakish D
    J Clin Psychiatry; 2001; 62 Suppl 26():5-9. PubMed ID: 11775091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission and functioning in major depressive disorder.
    Romera I; Perez V; Gilaberte I
    Actas Esp Psiquiatr; 2013; 41(5):263-8. PubMed ID: 24096391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving remission in major depressive disorder: the first step to long-term recovery.
    Kelsey JE
    J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 3):S6-10. PubMed ID: 15083991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive remission: a novel objective for the treatment of major depression?
    Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF
    BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving remission in major depressive disorder: the first step to long-term recovery.
    Kelsey JE
    J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 1):S6-10. PubMed ID: 16493144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder.
    Zuckerman H; Pan Z; Park C; Brietzke E; Musial N; Shariq AS; Iacobucci M; Yim SJ; Lui LMW; Rong C; McIntyre RS
    Front Psychiatry; 2018; 9():655. PubMed ID: 30564155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.
    Trivedi MH; Lin EH; Katon WJ
    CNS Spectr; 2007 Aug; 12(8 Suppl 13):1-27. PubMed ID: 17986951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features.
    Craig TJ; Grossman S; Bromet EJ; Fochtmann LJ; Carlson GA
    Compr Psychiatry; 2007; 48(6):497-503. PubMed ID: 17954133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional outcomes in MDD: established and emerging assessment tools.
    Endicott J; Dorries KM
    Am J Manag Care; 2009 Dec; 15(11 Suppl):S328-34. PubMed ID: 20088629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major depressive disorder: remission of associated symptoms.
    Trivedi MH
    J Clin Psychiatry; 2006; 67 Suppl 6():27-32. PubMed ID: 16848674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
    Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A primary care focus on the diagnosis and treatment of major depressive disorder in adults.
    Halaris A
    J Psychiatr Pract; 2011 Sep; 17(5):340-50. PubMed ID: 21926529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.